Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 11;24(1):32.
doi: 10.1186/s12882-023-03082-9.

NT-proBNP as predictor of major cardiac events after renal transplantation in patients with preserved left ventricular ejection fraction

Sebastian Schwab  1 , Daniel Pörner  2 , Carola-Ellen Kleine  2 , Roxana Werberich  2 , Louisa Werberich  2 , Stephan Reinhard  2 , Dominik Bös  3 , Christian P Strassburg  2 , Sibylle von Vietinghoff  2 , Philipp Lutz #  2 , Rainer P Woitas #  4
Affiliations

NT-proBNP as predictor of major cardiac events after renal transplantation in patients with preserved left ventricular ejection fraction

Sebastian Schwab et al. BMC Nephrol. .

Abstract

Background: For the improvement of outcome after renal transplantation it is important to predict future risk of major adverse cardiac events as well as all-cause mortality. We aimed to determine the relationship of pre-transplant NT-proBNP with major adverse cardiac events and all-cause mortality after transplant in patients on the waiting-list with preserved left ventricular ejection fraction.

Patients and methods: We included 176 patients with end-stage renal disease and preserved left ventricular ejection fraction who received a kidney transplant. MACE was defined as myocardial infarction (ST-segment elevation [STEMI] or non-ST-segment elevation [NSTEMI]), stroke or transient ischemic attack), coronary artery disease requiring intervention or bypass or death from cardiovascular causes.

Results: MACE occurred in 28/176 patients. Patients with NT-proBNP levels above 4350 pg/ml had 1- and 5-year survival rates of 90.67% and 68.20%, whereas patients with NT-proBNP levels below 4350 pg/ml had 1- and 5-year survival rates of 100% and 90.48% (p < 0.01). 1- and 5-year MACE-free survival rates were calculated as 78.82% and 74.68% for patients with NT-proBNP > 4350 pg/ml and 93.33% and 91.21% for patients with NT-proBNP < 4350 pg/ml (p < 0.01).

Conclusions: Pre-transplant NT-proBNP might identify renal transplant candidates at risk for MACE after transplant.

Keywords: Major cardiovascular event; NT-proBNP; Renal transplantation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Distribution of pre-transplant NT-proBNP levels
Fig. 2
Fig. 2
Overall survival. NT-proBNP and survival in a kidney transplantation cohort. A Kaplan–Meier curve of overall survival of patients with and without MACE; B survival of patients with NT-proBNP level lower or above 4350 pg/ml (p =  < 0.01); C survival of patients with given NT-proBNP values (p =  < 0.01)
Fig. 3
Fig. 3
MACE-free survival. NT-proBNP and incidence of MACE in a kidney transplantation cohort. A Kaplan–Meier curve of MACE-free survival in our cohort; B MACE-free survival of patients with NT-proBNP level lower or above 4350 pg/ml (p =  < 0.01); C MACE-free survival of patients with given NT-proBNP values (p =  < 0.01)
See this image and copyright information in PMC

References

    1. Wolfe RAV, Milforf E, Ojo A, Ettenger R, Agodoa L, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23):1725–1730. doi: 10.1056/NEJM199912023412303. - DOI - PubMed
    1. Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol. 2005;16(2):496–506. doi: 10.1681/asn.2004070580. - DOI - PubMed
    1. Harrison TG, Shukalek CB, Hemmelgarn BR, Zarnke KB, Ronksley PE, Iragorri N, et al. Association of NT-proBNP and BNP with future clinical outcomes in patients With ESKD: a systematic review and meta-analysis. Am J Kidney Dis. 2020;76(2):233–247. doi: 10.1053/j.ajkd.2019.12.017. - DOI - PubMed
    1. Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis. 2005;46(4):610–620. doi: 10.1053/j.ajkd.2005.06.017. - DOI - PubMed
    1. Gangji AS, Helal BA, Churchill DN, Brimble KS, Margetts PJ. Association between n-terminal propeptide b-type natriuretic peptide and markers of hypervolemia. Perit Dial Int. 2008;28(3):308–311. doi: 10.1177/089686080802800319. - DOI - PubMed

Publication types